Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523181 | 1.00 | MMP1 (0.64) | MMP1ADAM17ALDH1A1KMT2AMMP2 | |
| SCHEMBL8216398 | 1.00 | MMP1 (0.64) | MMP1ADAM17ALDH1A1KMT2AMMP2 | |
| SCHEMBL7216567 | 0.89 | MMP1 (0.80) | MMP1ADAM17MMP2PKM | |
| SCHEMBL2771228 | 0.83 | ALDH1A1 (0.72) | MMP1ADAM17ALDH1A1KMT2AMMP2 | |
| SCHEMBL5702221 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KMT2AMMP2TSHRMAPK1 | |
| SCHEMBL4669530 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KMT2AMMP2TSHRMAPK1 | |
| SCHEMBL5702094 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KMT2AMMP2TSHRMAPK1 | |
| SCHEMBL5885924 | 0.80 | ALDH1A1 (0.70) | ALDH1A1KMT2AMMP2ANPEPTSHR | |
| SCHEMBL5885922 | 0.80 | ALDH1A1 (0.70) | ALDH1A1KMT2AMMP2ANPEPTSHR | |
| SCHEMBL8221090 | 0.79 | MMP1 (0.51) | MMP1ADAM17ALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | MMP1 1917/4885ADAM17 3140/4885ALDH1A1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.